Clinical trial NCT01518998 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: fimasartan , amlodipine, placebo
SMILES: CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects who agreed to participate in this study and submitted the written informed
             consent

          2. Subjects aged 20 to 75 years

          3. Essential hypertension subjects who are measured more 90mmHg, less than 114mmHg of
             sitting diastolic blood pressure (SiDBP) at baseline(day 0).

          4. Subjects who considered to understand this study , be cooperative, and able to be
             followed-up whole of the study period.

        Exclusion Criteria:

          1. Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting
             systolic blood pressure (SiSBP)

          2. Patients with secondary hypertension

          3. Patients with significant investigations - abnormal renal function (Creatinine more
             1.5 times than upper limit of normal), abnormal liver function (AST, ALT more 2 times
             than upper normal), moderate fatty lever needed medication

          4. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L),
             Hyperkalemia(exceeded 5.5mmol/L)

          5. Patients with sodium ion or body fluid is depleted and not able to correct

          6. Patients with hypotension who has sign and symptom

          7. Patients with surgical and medical disease it is able to be affect to absorption,
             distribution, metabolism, excretion

          8. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c > 9%,
             regimen change of oral hypoglycemic agent, using insulin)

          9. Patients with severe heart disease, ischemic heart disease within 6months, peripheral
             vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary
             Artery Bypass Graft (CABG)

         10. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter
             or other significant arrhythmia

         11. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral
             valve disease

         12. Patients with severe cerebrovascular disease

         13. Patients with wasting disease, autoimmune disease, connective tissue disease at
             present and/or previous.

         14. Patients with known severe or malignancy retinopathy

         15. Patients with hepatitis B or C or HIV positive reaction

         16. Patients who have a story or evidence of alcohol or drug abuse within 2years

         17. Patients who are measured the mean difference of mean blood pressure of both arm under
             SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit

         18. Patients with history of allergic reaction to any angiotensin II antagonist

         19. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         20. Patients with the medical histories of malignant tumor within 5years, except local
             basal cell carcinoma of the skin

         21. Childbearing and breast-feeding women

         22. Female who plan to become pregnancy or have a possibility of pregnancy but don't
             prevent conception with acknowledged methods

         23. Patients who took medicine within 12 weeks from screening visit or is going on the
             progress of other clinical trial

         24. Subject who are judged unsuitable to participate in this study by investigator